
Wall Street Journal - March 3, 1984
The new test will cost just $5 per unit of blood but will force the blood bank to discard about 6% of the 10,000 units the blood bank draws each month. Dr. Herbert Perkins, the blood bank's scientific director, said the test will "enhance the safety of the community's blood supply and provide an added safety net for screening donors at high risk for AIDS. "
Nationwide, at least 70 AIDS patients, 46 transfusion recipients and 24 hemophiliacs treated with plasma products, appear to have blood ties to the mysterious epidemic. AIDS causes the collapse of the immune systems of its victims, leaving them vulnerable to rare cancers, pneumonia and other socalled opportunity infections.
High risk groups for developing the disease include male homosexuals with multiple partners, heroin addicts, and Haitians.
Irwin Memorial has long tested blood for evidence of past infection from hepatitis-B. That test will continue to be used. The new test, known as the core-antibody test, will tighten the screening against hepatitis-B and detect past infection of another strain of the virus known as non-A-non-B.
Irwin said that about 90% of all people in the high-risk groups for developing AIDS carry the core antibody for hepatitis. "The test therefore will help ensure that no blood given by a donor at high risk for AIDS will be transfused," the blood bank said.
Irwin said that it will begin the new test May 1. The blood bank added that it will soon offer donors a discrete post-donation method of recalling their donation if they believe their blood may not be safe to transfuse. The measure is designed to accommodate some gays who are pressured to donate blood during an office blood drive.
Irwin, like most blood banks around the country, currently screens for AIDS by asking donors a series of medical questions. This "voluntary deferral" program was the subject of a page one story in The Wall Street Journal earlier this month.
840330
WJ840303
Copyright © 1984 - The Wall Street Journal. Reproduction of this article (other than one copy for personal reference) must be cleared through the WSJ Permissions Desk.
AEGiS is a 501(c)3, not-for-profit, tax-exempt, educational corporation. AEGiS is made possible through unrestricted funding from Boehringer Ingelheim, Bridgestone/Firestone Charitable Trust, Elton John AIDS Foundation UK, the National Library of Medicine, AIDS Walk of Orange County, and donations from users like you.
Always watch for outdated information. This article first appeared in 1984. This material is designed to support, not replace, the relationship that exists between you and your doctor.
AEGiS presents published material, reprinted with permission and neither endorses nor opposes any material. All information contained on this website, including information relating to health conditions, products, and treatments, is for informational purposes only. It is often presented in summary or aggregate form. It is not meant to be a substitute for the advice provided by your own physician or other medical professionals. Always discuss treatment options with a doctor who specializes in treating HIV.
Copyright ©1980, 1984. AEGiS. All materials appearing on AEGiS are protected by copyright as a collective work or compilation under U.S. copyright and other laws and are the property of AEGiS, or the party credited as the provider of the content. .